Overview

Pulmonary Gas Exchange Response to Indacaterol in COPD

Status:
Unknown status
Trial end date:
2015-11-01
Target enrollment:
Participant gender:
Summary
To evaluate the pulmonary gas exchange response to a therapeutic high dose of inhaled indacaterol (300 mcg) in 20 outpatients with stable symptomatic COPD B and D GOLD 2011 groups. Measurements on a single day before and after 60 and 120 minutes of indacaterol will include arterial PO2, PaCO2 and pH. AaPO2; SaO2 (by pulse oximetry) and oxygen and carbon dioxide in exhaled breath, systemic arterial pressure and heart rate will also be measured/calculated. Cardiac output will be directly measured by bio-impedance.
Phase:
Phase 4
Details
Lead Sponsor:
Hospital Clinic of Barcelona